These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34364544)

  • 1. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
    Eslam M; Alkhouri N; Vajro P; Baumann U; Weiss R; Socha P; Marcus C; Lee WS; Kelly D; Porta G; El-Guindi MA; Alisi A; Mann JP; Mouane N; Baur LA; Dhawan A; George J
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):864-873. PubMed ID: 34364544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
    Imai J; Takashimizu S; Suzuki N; Ohshinden K; Sawamoto K; Mishima Y; Tsuruya K; Arase Y; Yamano M; Kishimoto N; Yamada C; Inoue N; Moriyama K; Baba A; Suzuki H; Kagawa T; Nishizaki Y
    Sci Rep; 2024 Jun; 14(1):13411. PubMed ID: 38862756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
    Eslam M; Newsome PN; Sarin SK; Anstee QM; Targher G; Romero-Gomez M; Zelber-Sagi S; Wai-Sun Wong V; Dufour JF; Schattenberg JM; Kawaguchi T; Arrese M; Valenti L; Shiha G; Tiribelli C; Yki-Järvinen H; Fan JG; Grønbæk H; Yilmaz Y; Cortez-Pinto H; Oliveira CP; Bedossa P; Adams LA; Zheng MH; Fouad Y; Chan WK; Mendez-Sanchez N; Ahn SH; Castera L; Bugianesi E; Ratziu V; George J
    J Hepatol; 2020 Jul; 73(1):202-209. PubMed ID: 32278004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    Eslam M; George J
    J Hepatol; 2020 Dec; 73(6):1575. PubMed ID: 32933781
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes.
    Mastromauro C; Polidori N; Giannini C
    Curr Opin Pediatr; 2022 Aug; 34(4):414-422. PubMed ID: 35836399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
    Ng CH; Huang DQ; Nguyen MH
    Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.
    Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N
    Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.
    Yilmaz Y; Byrne CD; Musso G
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):345-352. PubMed ID: 33270482
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective.
    Nardolillo M; Rescigno F; Bartiromo M; Piatto D; Guarino S; Marzuillo P; Miraglia Del Giudice E; Di Sessa A
    World J Gastroenterol; 2024 Apr; 30(15):2081-2086. PubMed ID: 38681989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relation of risk factors between metabolic syndrome and nonalcoholic fatty liver disease in children and adolescents].
    Smolka V; Ehrmann J; Tkachyk O; Zápalka M
    Cas Lek Cesk; 2014; 153(2):91-7. PubMed ID: 24797780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.
    Xian YX; Weng JP; Xu F
    Chin Med J (Engl); 2020 Dec; 134(1):8-19. PubMed ID: 33323806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.
    Vimalesvaran S; Vajro P; Dhawan A
    Hepatol Int; 2024 Oct; 18(Suppl 2):873-883. PubMed ID: 38879851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.